The direct-medical costs associated with interferon-based treatment for Hepatitis C in Vietnam
Authors:
- Huyen Anh NguyenHNHuyen Anh Nguyen
- Graham S. CookeGCGraham S. Cooke
- Jeremy N. DayJDJeremy N. Day
- Barnaby FlowerBFBarnaby Flower
- Le Thanh PhuongLPLe Thanh Phuong
- Trinh Manh HungTHTrinh Manh Hung
- Nguyen Thanh DungNDNguyen Thanh Dung
- Dao Bach KhoaDKDao Bach Khoa
- Le Manh HungLHLe Manh Hung
- Evelyne KestelynEKEvelyne Kestelyn
- Guy E. ThwaitesGTGuy E. Thwaites
- Nguyen Van Vinh ChauNCNguyen Van Vinh Chau
Open Access
- 4 September 2019
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 4, 129
Abstract
Background: Injectable interferon-based therapies have been used to treat hepatitis C virus (HCV) infection since 1991. International guidelines have now moved away from interferon-based therapy towards direct-acting antiviral (DAA) tablet regimens, because of their superior efficacy, excellent side-effect profiles, and ease of administration. Initially DAA drugs were prohibitively expensive for most healthcare systems. Access is now improving through the procurement of low-cost, generic DAAs acquired through voluntary licenses. However, HCV treatment costs vary widely, and many countries are struggling with DAA treatment scale-up. This is not helped by the limited cost data and economic evaluations from low- and middle-income countries to support HCV policy decisions. We conducted a detailed analysis of the costs of treating chronic HCV infection with interferon-based therapy in Vietnam. Understanding these costs is important for performing necessary economic evaluations of novel treatment strategies. Methods: We conducted an analysis of the direct medical costs of treating HCV infection with interferon alpha (IFN) and pegylated-interferon alpha (Peg-IFN), in combination with ribavirin, from the health sector perspective at the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, in 2017. Results: The total cost of the IFN treatment regimen was estimated to range between US$1,120 and US$1,962. The total cost of the Peg-IFN treatment regimen was between US$2,156 and US$5,887. Drug expenses were the biggest contributor to the total treatment cost (54-89%) and were much higher for the Peg-IFN regimen. Conclusions: We found that treating HCV with IFN or Peg-IFN resulted in significant direct medical costs. Of concern, we found that all patients incurred substantial out-of-pocket costs, including those receiving the maximum level of support from the national health insurance programme. This cost data highlights the potential savings and importance of increased access to generic DAAs in low- and middle-income countries and will be useful within future economic evaluations.Keywords
Funding Information
- Wellcome Trust (206296, 106680)
- medical research coun (MR/P025064/1)
This publication has 20 references indexed in Scilit:
- Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology CommissionThe Lancet Gastroenterology & Hepatology, 2019
- Current challenges and possible solutions to improve access to care and treatment for hepatitis C infection in Vietnam: a systematic reviewBMC Infectious Diseases, 2017
- Health Economic Evaluations of Sofosbuvir for Treatment of Chronic Hepatitis C: a Systematic ReviewApplied Health Economics and Health Policy, 2016
- Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting AntiviralsPharmacoEconomics, 2016
- A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis CJournal of Hepatology, 2012
- A systematic review of the cost–effectiveness of peginterferon alfa-2b in the treatment of chronic hepatitis CExpert Review of Pharmacoeconomics & Outcomes Research, 2007
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Side Effects of Interferon-α TherapyPharmacy World & Science, 2005
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trialsHepatology, 1997